## Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

## Listing of Claims:

## 1-18. Canceled

19. (Currently Amended) A purified <u>or recombinant</u> polypeptide comprising the amino acid sequence of SEQ ID NO: 16;

an amino acid sequence that differs from SEQ ID NO: 16 by one or more conservative amino acid substitutions; or

an amino acid sequence that differs from SEQ ID NO: 16 by a single mutation, wherein the single mutation represents a single amino acid deletion, insertion or substitution.

20. (Currently Amended) A The purified or recombinant polypeptide of claim 19 wherein said polypeptide comprises comprising an amino acid of SEQ ID NO: 16.

## 21-24. Canceled

- 25. (Original) A method of screening for potential human therapeutic agents, said method comprising contacting a C58 polypeptide with a candidate compound; and determining if the candidate compound selectively binds to the C58 polypeptide.
- 26. (Original) The method of claim 25 wherein the C58 polypeptide is expressed on the surface of a cell.
- 27. (Original) An antibody that binds specifically to the protein of SEQ ID NO: 16.
- 28. (Original) The antibody of claim 27 wherein the antibody binds to amino acids 22-112 of SEQ ID NO: 16.
- 29. (Original) An antigenic composition comprising a C58 polypeptide and a pharmaceutically acceptable carrier.